Older man rising from chair

(© jclaudiopph - stock.adobe.com)

A Faulty Nerve Signal May Help Explain Weakness in Old Age

In A Nutshell

  • Older adults with leg weakness had nerve signals fail to reach muscle at up to 35% of tested connection points in some people.
  • Aged muscle had less of a channel called NaV1.4 where nerves connect, and blocking it in healthy adult rats caused similar signal problems.
  • An experimental drug boosted muscle force and grip strength in old rats, but the benefit faded about a day after dosing stopped.
  • The drug was tested only in animals, and the human leg study involved just 18 people.

Struggling to rise from a chair in old age may have less to do with shrinking muscle than with a message that never arrives. In older adults with real leg weakness, signals a nerve sends to trigger a muscle failed to arrive at up to 35% of the connection points tested in some people. Timing glitches in those signals ran about 250% higher than in younger adults, and both problems worsened as legs got weaker.

A study in the Journal of Clinical Investigation linked the breakdown to the loss of NaV1.4, a tiny gateway on muscle fibers that lets a nerve’s signal switch them on. Muscle fibers from old mice still fired normally when stimulated directly, which points to the connection rather than the muscle itself. In old rats, an experimental drug that worked around the problem boosted muscle force and improved grip strength over a week of dosing.

Researchers from the University of Missouri, Ohio University, and other institutions, plus employees of NMD Pharma, which sponsored the work in part, combined tests in older volunteers with experiments in mice and rats. These results push back on the idea that muscle loss alone explains why so many older people struggle to climb stairs or carry groceries.

Older Adults With Muscle Weakness Showed Failed Nerve-to-Muscle Signals

Ten adults averaging 86 years old, 40% of them women, all reporting physical limitations, took part, along with eight younger and middle-aged adults averaging about 30 for comparison. Nine of the 10 older participants had clear leg weakness. After strength tests and thigh scans, thin needle electrodes in the thigh sent small pulses to a nerve and tracked how single muscle fibers answered.

Healthy muscle answers every pulse on cue. In the weak older adults, answers came back with erratic timing, and some did not come back at all. Even when strength was measured relative to muscle size, weaker legs went with worse signals, so shrinking muscle alone did not explain the problem. Earlier human studies relied on indirect methods, and none had used this needle technique in older adults.

Why Muscles Weaken With Age
Older adults with leg weakness showed nerve signals failing to reach muscle, and a drug improved strength in old rats. (Image by StudyFinds)

Aged Muscle Had Fewer Sodium Channels Where Nerves Connect

In animal experiments, trouble showed up where nerve meets muscle. There, fewer fibers in old mice and rats kept the extra electrical boost that young muscle has as backup against missed signals. Imaging revealed a likely reason: the animals had less NaV1.4, a channel found only in skeletal muscle, packed into that spot. In mice, the loss hit fast-twitch muscles, used for quick, powerful movements, but spared an endurance-built slow-twitch muscle.

Human tissue showed a similar pattern. Hand-muscle samples taken during reconstructive surgery, from three older and three younger people, looked structurally normal in both groups, yet the older samples had clearly less NaV1.4. The samples came from surgical patients, not the leg-weakness volunteers, so the human link is indirect.

To test whether losing the channel was enough to cause the problem, researchers injected a toxin that temporarily blocks it into adult rats’ leg muscles, three rats per group. Those rats developed timing errors and signal failures similar to those seen in aged animals and older volunteers.

Old rats turned out to have signal failures much like the human volunteers, with blocked signals at about 30% of connection points on average. Next, the team tried to work around the missing channel with a drug that releases a brake on how easily muscle fibers fire. In nine old rats, one dose raised electrically stimulated muscle force by an average of 14%, recovering more than half the strength gap between old and young rats. Three old rats given a placebo lost a little force.

A blinded week-long trial then tested grip strength, a measure of voluntary effort. Five 20-month-old male rats got the drug and four got a placebo. Over the first four days, grip strength rose about 11% in the treated group and fell about 10% in the placebo group, but about a day after dosing stopped, the difference vanished, so the benefit lasted only while the drug was active.

Mizzou researchers. Credit: University of Missouri

Current approaches center on exercise and nutrition, which work unevenly and are hard to keep up, while drugs built to add muscle mass have produced only modest gains in function. Targeting the nerve-muscle connection is a different route, and a drug that worked could, in theory, help people for whom exercise is hard. The authors add that the same needle test might someday identify which patients are likely to respond. The human leg study involved just 18 people, and the animal work came mostly from male animals in small groups.

Weakness in old age may not be simply worn-out muscle. A failing connection between nerve and muscle looks like a real contributor, and potentially a treatable one, but only trials in people can show whether it is.


Disclaimer: This article is based on a published research paper and is intended for general informational purposes only. It is not medical advice. Results from animal studies do not always apply to people, and readers should speak with a qualified healthcare provider before making any health decisions.


Paper Notes

Limitations

Only 10 older adults and eight younger controls took part in the clinical portion, a small group that limits how broadly the results apply. Only one older participant lacked clinically meaningful leg weakness, so the study could not compare weak and non-weak older adults, a comparison the authors say future studies need to make. The study was cross-sectional, a single snapshot in time, and the control group (ages 20 to 45) was decades younger than the older group. The human NaV1.4 analysis used biopsy samples from three older and three younger people, taken from different individuals than the leg-weakness volunteers, so the connection between channel loss and weakness in people is indirect. Most animal experiments used only male animals, which the authors attributed to the greater availability of aged male animals across sites, and several groups were small (three rats per group in the toxin experiment, five and four in the week-long grip trial). The drug, NMD1226, lost its effect within about a day of stopping, and long-term safety and effectiveness were not examined. The authors also noted that the upstream reasons NaV1.4 declines with age remain unclear, and that a proposed explanation involving calcium channel coupling in muscle is inferential because it was not directly measured in aged muscle.

Funding and Disclosures

NMD Pharma sponsored the studies in part and specifically funded the clinical study (STAMINA, NCT04904926). Jeanette Jeppesen Morgen, Pernille Bogetofte Thomasen, Thomas Groennebaek, Martin Skov, Martin Broch-Lips, Jane Bold, John Hutchison, Jorge Quiroz, Jeppe Blichfeldt Winther, and Thomas Holm Pedersen were or are employed by NMD Pharma and may own or hold options or restricted stock units in the company, or hold patents on the compounds. W. David Arnold received grant funding, consulting fees, and travel support from NMD Pharma. Lauren A. Fish and Justin R. Fallon are coinventors on patents held by Brown University covering manipulation of the MuSK/BMP pathway, and Fallon is a cofounder of Bolden Therapeutics, which has licensed those patents. Thomas H. Gillingwater has provided advisory services for Roche, Novartis, and LifeArc. Additional funding came from the National Institutes of Health (grants R01AG078129, R01AG067758, and AR074985), Anatomy@Edinburgh at the University of Edinburgh, and a PhD studentship from King Saud bin Abdulaziz University for Health Sciences through the Saudi Cultural Bureau in London.

Publication Details

This study, titled “Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition,” was authored by W. David Arnold, Jeanette Jeppesen Morgen, Pernille Bogetofte Thomasen, Martin Broch-Lips, Leatha A. Clark, Thomas Groennebaek, Martin Skov, Jeppe Blichfeldt Winther, Abdullah Ramadan, Philippa A. Rust, Jessica H. Myers, Fereshteh B. Darvishi, Anna R. Dashtmian, Lauren A. Fish, Deepti Chugh, Jane Bold, Jorge Quiroz, John Hutchison, Hiroshi Nishimune, Ross A. Jones, Xueyong Wang, Justin R. Fallon, Thomas H. Gillingwater, Mark M. Rich, Thomas Holm Pedersen, and Brian C. Clark. It was published online July 9, 2026, in The Journal of Clinical Investigation, Volume 136, Issue 17 (September 1, 2026), article e190646, under an open access Creative Commons Attribution 4.0 license. DOI: https://doi.org/10.1172/JCI190646. Correspondence: W. David Arnold, University of Missouri ([email protected]), and Brian C. Clark, Ohio University Heritage College of Osteopathic Medicine ([email protected]).

About StudyFinds Analysis

Called "brilliant," "fantastic," and "spot on" by scientists and researchers, our acclaimed StudyFinds Analysis articles are created using an exclusive AI-based model with complete human oversight by the StudyFinds Editorial Team. For these articles, we use an unparalleled LLM process across multiple systems to analyze entire journal papers, extract data, and create accurate, accessible content. Our writing and editing team proofreads and polishes each and every article before publishing. With recent studies showing that artificial intelligence can interpret scientific research as well as (or even better) than field experts and specialists, StudyFinds was among the earliest to adopt and test this technology before approving its widespread use on our site. We stand by our practice and continuously update our processes to ensure the very highest level of accuracy. Read our AI Policy (link below) for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

John Anderer

Associate Editor